Canopy Growth (NASDAQ:CGC – Get Free Report) and Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Canopy Growth and Ono Pharmaceutical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Canopy Growth | 1 | 1 | 2 | 0 | 2.25 |
| Ono Pharmaceutical | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares Canopy Growth and Ono Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Canopy Growth | -73.03% | -28.21% | -17.97% |
| Ono Pharmaceutical | 15.04% | 9.41% | 7.39% |
Institutional & Insider Ownership
3.3% of Canopy Growth shares are held by institutional investors. 0.4% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Canopy Growth and Ono Pharmaceutical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Canopy Growth | $308.32 million | 0.82 | -$190.29 million | ($0.51) | -1.10 |
| Ono Pharmaceutical | $3.43 billion | 2.04 | $436.04 million | $1.01 | 14.75 |
Ono Pharmaceutical has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Canopy Growth has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Summary
Ono Pharmaceutical beats Canopy Growth on 8 of the 13 factors compared between the two stocks.
About Canopy Growth
Canopy Growth is a Canadian cannabis company that produces and sells cannabis products for adult-use and medical markets. Its offerings include dried flower, oils, capsules, edibles, beverages and other cannabis formats, marketed under brands such as Tweed and 7ACRES. The company also serves medical cannabis customers in international markets and has a presence in the cannabis vaporization business through Storz & Bickel. Its activities and product availability vary by market and are subject to local regulations.
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Founded in 1717 as a medicine wholesaler, the company is headquartered in Osaka. Ono’s research and product portfolio spans areas including oncology, immunology, neurology and diabetes. A notable product is Opdivo (nivolumab), an immuno-oncology medicine developed through a collaboration involving Ono and Medarex, which was later acquired by Bristol Myers Squibb.
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
